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BACKGROUND
The idea of using information about a subject to detect subclinical disease states and to predict
future health events has great appeal. The notion is currently motivating much biotechnologic
medical research. We hope to use biomarkers derived from new proteomic and genomic technologies
to identify subjects that have or are very likely to develop cancer or other diseases [1]. In addition
we hope to use these modern technologies and others to make precise diagnoses and more accurate
prognoses of patients with disease, to help with decisions about treatment, and to monitor response
to treatment. The use of biomarkers and risk factors in this way is not a new notion in medical
practice. Prediction risk scores are commonly used. Examples include the Framingham risk score
for cardiovascular events [2] and the Gail model risk score for breast cancer [3]. Even more common,
epidemiologists have identified a myriad of disease specific risk factors that have been used alone,
or in combination in public health practice. Clinical epidemiologists have analogously identified a
multitude of factors that are associated with the clinical course of patients diagnosed with disease.
The statistical evaluation of factors, scores and biomarkers for assessing an individual’s current
status or future health outcome is the topic of this paper. We use the generic term ‘marker’ for the
factor, score or biomarker and ‘outcome’ for that which is predicted or detected. We show in this
paper that strong statistical associations between outcome and marker do not necessarily imply
that the marker can usefully discriminate between those individuals likely to have the outcome
from those who do not. Traditional statistical methods used by epidemiologists to assess etiologic
associations are not adequate to determine the potential performance of a marker for classifying
or predicting risk for individuals. This important point is not widely appreciated and may explain
to some extent the disappointing performance of many identified “markers” when they are used
to predict outcome for individuals. As we proceed to develop technologically sophisticated tools
for individual level prediction and classification, for so-called ‘personalized medicine,’ we must be
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careful to use appropriate statistical techniques in evaluating research studies aimed at assessing
their performance. We describe some appropriate techniques in this paper.
The performance of a marker may change with the circumstance in which it is applied. Char-
acteristics of the population, or the assay technique (if the marker is a biomarker) for example,
may lead to better or worse performance. It is important to understand and quantify variations in
the performance of a marker. We show how such questions can be addressed statistically and the
pitfalls of using some common epidemiological methods for this purpose. In addition we discuss the
evaluation of a marker in the presence of other information that is predictive of outcome. This may
include risk factor data or other markers. The question is how to evaluate the incremental value
of a marker for distinguishing cases from controls. Again we show that traditional epidemiologic
methods can lead to false conclusions and we describe more appropriate statistical methods.
ASSOCIATION VERSUS CLASSIFICATION
Consider a binary risk factor as a marker. For example, unopposed estrogen replacement therapy
is considered to be a strong risk factor for development of endometrial cancer [4]. It has a relative
risk of about 3.0 associated with it, which is to say that in a case-control study the odds ratio
for comparing cases versus controls in regards to ‘ever having used estrogen replacement therapy’
is about 3.0. Reporting the odds ratio or relative risk as a measure of association is typical in
epidemiologic studies of etiologic risk factors and is now unfortunately commonly employed for
studies of predictive markers as well. See for example Cui et al. (2003) in a recent issue of Science
and Rhodes et al. (2003) in a recent issue of Journal of the National Cancer Institute [5, 6].
Examples from other popular journals are Ridker et al (2000), Zhang et al. (2001), Liou et al.
(1999), and Hogue et al. (2001) [7, 8, 9, 10]. We note that the goals of etiologic risk factor studies
are quite different from the sorts of studies we consider here, where markers are to be used for
classifying individuals. The statistical considerations therefore also differ between such studies.
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The accuracy or validity of a binary marker for classifying individuals is better summarized in
a case-control study by reporting its true positive fraction (TPF, also known as sensitivity) and its
false positive fraction (FPF, also known as 1-specificity):
TPF = Prob[marker positive | outcome positive]
and
FPF = Prob[marker positive | outcome negative].
A perfect marker will have TPF = 1 and FPF = 0. How close TPF should be to 1 and how close
FPF should be to 0 in order for the marker to be useful for individual level classification depends
on the context. Nevertheless the values cannot be too far away from the ideal values in order for
an individual to believe the prediction.
The odds ratio (OR) can be written as a simple function of (FPF, TPF) [11]:
OR =
(
TPF
1− TPF
)
×
(
1− FPF
FPF
)
Figure 1 shows this relationship. Accuracy points (FPF, TPF) that yield the same value of the odds
ratio are shown. Observe that an odds ratio of 3.0 is not consistent with an “accurate” marker.
Suppose for example that a marker labels as many as 10 percent of controls (outcome negatives) as
positive and has an odds ratio of 3.0 associated with it. We see from Figure 1 that it identifies only
about 25 percent of the cases (outcome positives). That is, 75 percent of the cases are not picked
up by the marker. As another example, suppose that a marker with OR=3 detects 80 percent of
cases. The plot shows that it must mislabel almost 60 percent of the controls. Clearly this is not
a marker that is useful for individual level classification or prediction. The figure shows that even
weakly accurate markers are associated with odds ratios (or relative risks) that are far larger than
those traditionally considered strong in epidemiologic studies of association.
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When the marker, denoted now by X , is continuous, its association with outcome status, D = 1
for case and D = 0 for control, is also often summarized with an odds ratio. Consider the logistic
regression model
Prob(D = 1|X) = exp(α+ βX)/{1+ exp(α+ βX)}
The odds ratio per unit increase in X is given by exp(β). The size of the odds ratio depends on the
units in which X is measured. In Figure 2 we have scaled X so that a unit increase represents the
difference between the 16th and 84th percentiles of X in the controls (i.e., 2 standard deviations =
1 unit). The distribution of X in controls is represented as normal with mean 0, which is general
in the sense that data can always be transformed to this scale. Assuming that, for cases, X is also
normally distributed with the same standard deviation as controls, Figure 2 shows their separation
from controls for various values of the odds ratio. We see again that values of the OR considered
large in traditional epidemiologic studies are derived from marker distributions that are largely
overlapping (Figure 2).
Receiver operating characteristic (ROC) curves corresponding to each of the pairs of marker
distributions in Figure 2 are shown in Figure 3. Each point on an ROC curve represents the decision
criterion that is positive if X exceeds a threshold c. The FPF and TPF values associated with that
criterion is one point on the curve, and by varying c from +∞ to −∞, the (FPF, TPF) points
corresponding to all possible thresholds are shown. Although they appear similar, Figure 1 differs
from Figure 3. Figure 1 concerns binary markers only, with odds ratios defined in the usual way
for a binary marker. Many different markers are represented on the same curve in Figure 1 if their
odds ratios are the same. The odds ratios here in Figure 3 relate to a unit increase in a continuous
marker and the ROC curve concerns different decision criteria resulting from thresholding that
single continuous marker.
We see from Figure 3 that when the OR associated with a unit increase in the continuous
5
http://biostats.bepress.com/uwbiostat/paper211
marker X is 3.0, regardless of the threshold chosen, the (FPF, TPF) values associated with the
corresponding decision criterion generally would not be adequate for individual level classification.
In fact unless the OR per unit increase in X is at least 16, marker based decision criterion seem to
be very inaccurate. Even with OR = 16, a marker based criterion that yields 10 percent FPF at a
threshold fails to detect over 40 percent of cases using that threshold. As another example, it will
falsely detect as many as 30 percent of controls if a threshold that yields 80 percent of the cases is
used.
Frequently, continuous markers are grouped to form categorical covariates, allowing the analyst
to avoid specific assumptions about the shape of the log (odds) function. For each of the marker
distributions shown in Figure 2, we also categorized both cases and controls based on the quartile
cut-points from the control population. The odds ratios for each quartile relative to the lowest
quartile is calculated and displayed in Table 1. The solid circle points shown on the ROC curves
in Figure 3 are those associated with using each of the three quartile cut-points to classify subjects
as positive or negative for disease. Similar to our observations for the binary and continuous
marker settings, even if the odds ratio for an upper quartile versus the lowest quartile is of a
large magnitude, the corresponding points on the ROC curves for each cut-point show poor ability
to classify cases and controls. For example, when the OR for the upper quartile vs. the lowest
quartile is 4.1, if we use the upper quartile to define a positive test result, only 45 percent of cases
are correctly classified while 25 percent of controls were incorrectly identified.
In summary, there are two key points that we wish to make based on Figures 1, 2 and 3. The
first, as previously stated, is that markers with odds ratios of the order that are considered strong
in traditional epidemiologic research, are not adequate for discriminating between those who do
and do not have an outcome of interest. Extremely strong associations are needed. The second is
that odds ratios in and of themselves do not characterize the discriminatory capacity of a marker.
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The odds ratio is a simple scalar measure of association between marker and outcome. It does not
characterize the discrimination between cases and controls that can be achieved by a marker since
many different pairs of true and false positive fractions are consistent with a particular value of
OR. In the next section we discuss alternatives to the odds ratio that can be used in case-control
studies to evaluate markers.
HOW TO QUANTIFY DISCRIMINATION IN A CASE-CONTROL STUDY
Classification Error Rates
Characterization of the discriminatory capacity of a binary marker has already been addressed
in Section 2. The true and false positive fractions provide a description. Although predictive values
(PV) are also of great interest, where positive PV = P[D = 1| marker positive] and negative PV =
P[D = 0| marker negative], these entities essentially require either a cohort study design where the
sample prevalence reflects the population prevalence or some external estimates of prevalence that
pertain to the population from which cases and controls are drawn. On the other hand, TPF and
FPF are defined conditional on outcome status and so can be estimated from a case-control study
where sampling is dependent on outcome. Diagnostic likelihood ratios have also been promoted as
measures to characterize the accuracy of a binary marker [12] but are not very popular in practice.
It is interesting that the characterization of accuracy requires two parameters, TPF and FPF
say, while association measures such as the odds ratio or correlation coefficient (for continuous
markers) are generally one dimensional. The characterization with (FPF, TPF) acknowledges that
false positive and false negative errors are not equivalent and must be reported separately [13].
The ROC curve is the natural generalization of (FPF, TPF) to accommodate settings where
the marker is continuous. It describes the whole set of potential (FPF, TPF) combinations that are
possible with positivity criteria based on the marker. The raw distributions and ROC curves for
two pancreatic cancer biomarkers are shown in Figures 4 and 5 [14]. Observe that the ROC curve
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does not depend on how the marker is coded. Changing the units in which the marker is measured
has no impact on its ROC curve. This contrasts with logistic regression models where, as noted
above, the odds ratio must be interpreted according to a unit increase in the value of X . Moreover,
ROC curves provide a natural common scale for comparing different markers even when they are
measured in completely different units. For example a marker that measures a concentration in
serum can be compared with one that measures flight time per unit charge derived from protein
mass spectrometry. In contrast, because odds ratios are interpreted per unit increase in the marker,
odds ratios for two markers may not be comparable. This is a key advantage of ROC curves.
MODIFIERS OF PREDICTOR PERFORMANCE
A variety of factors (or covariates) may affect how well a marker performs. For example, higher
breast density makes mammographic readings less accurate [15]. Factors beyond the subject are
often important too. The assay technique or the expertise of the lab technician can affect how well a
biomarker measure performs. In audiology, the location in which the hearing test is done can affect
the capacity of the test to detect hearing loss. If one can establish which covariates influence the
performance of a marker then one may use this information to optimize the marker measurement.
On the other hand it can suggest settings or populations for which the marker is less useful and
where alternative markers should be sought.
Not Traditional Effect Modification
We continue to denote the marker by X and denote covariates that may affect the performance
of the marker by Z. In epidemiology one typically uses a logistic regression model with statistical
interaction between covariates and the marker of interest to evaluate if there is ‘effect modification.’
Mathematically we write
logitP [D = 1|X,Z] = α + β1X + β2Z + β3XZ.
Evaluating the size and significance of β3, the interaction term, asks if the odds ratio associated
8
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with X varies with Z. However, since we have already established that the odds ratio does not
properly characterize marker performance, it follows that this approach does not address questions
about Z affecting the performance of X as a marker.
As a simple example consider the data shown in Table 2 where X and Z are binary. One is
considering to use the markerX as a screening device and, to make the discussion concrete, suppose
that the covariate Z is gender (Z = 1 for females and Z = 0 for males). The odds ratio associated
with X is exactly the same for males as for females. That is, Z is not an effect modifier in the
sense of altering the association between X and disease D when association is parameterized by the
odds ratio. It appears to these authors however, that at least for the purposes of disease screening,
X performs better in females (Z = 1) than in males (Z = 0). Almost all cases are detected in
both circumstances (TPF = 0.97 and TPF = 0.94) but twice as many controls screen positive
in the male population where FPF=0.06 versus in the female population where FPF=0.03. For
widespread screening of healthy populations it is critical to keep the number of false positive results
extremely low in order that the program be affordable and acceptable to healthy people. Therefore
the lower FPF observed in females makes it a better screening marker in that population.
Statistical Assessment
How then should one assess if a covariate affects the performance of a marker? When the marker
is binary one can simply determine to what extent the TPFs vary with Z and to what extent the
FPFs vary with Z. We made this assessment already informally for the data in Table 2. Formal
statistical techniques can be applied to test a hypothesis such as H0 : FPF(Z = 1) = FPF(Z = 0)
or to quantify the difference between FPF(Z = 1) and FPF(Z = 0) on some scale. The FPFs and
TPFs are binomial proportions and the usual techniques of Pearson chi-squared statistics and so
forth can be applied. Inference about FPFs uses data only for controls (D = 0) and inference about
TPFs uses data only for cases (D = 1). For example, using the data from Table 2 the comparison
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of FPFs results in p = 0.002 from a chi-squared test. Writing
FPF(Z) = P (X = 1|D = 0, Z)
we see that logistic regression techniques can be applied to data for controls with the marker as the
dependent variable and covariates Z as the independent variables to establish how the FPF varies
with Z. Regression techniques may be preferable when there are multiple components to Z or if Z
is continuous. Similarly logistic regression can be applied to data for the cases to establish how
TPF(Z) = P (X = 1|D = 1, Z)
varies with Z. We refer to Leisenring, Pepe and Longton (1997), Smith and Hadgu (1992), and
Pepe (2003) (Section 3.5) [16, 17, 18], for illustrations and in-depth discussion.
For a continuous marker, one needs to determine if the ROC curves for X vary with Z. There
are various ways to do this. If Z is dichotomous one can plot separate ROC curves for X using
data for the two groups or circumstances defined by Z. Statistical techniques to compare ROC
curves have been developed and are included in some software packages including Stata (2003)
[19]. Data for prostate specific antigen (PSA) reported by Etzioni et al. (1999) [20] are shown in
Figure 6 for men <65 years of age and men >65 years of age. Although the study measured PSA
repeatedly over time we only use data for the last time point (prior to diagnosis for cases). The
classic statistic for comparing two ROC curves is the difference in the areas under the empirical
ROC curves. The difference is not statistically significant (p = 0.44). Thus, there is no evidence
in this sample that age affects the capacity of PSA to distinguish cases with prostate cancer from
age-matched controls.
Similar techniques can be used to compare the performances of two different markers in the
same population. The ROC curves in Figure 4 for CA-125 and CA-19-9 [14] (Wieand et al., 1989)
are statistically significantly different (p < 0.01). This p-value is based on the difference in empirical
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areas under the ROC curves applied to paired data [21]. Methods based on comparing ROC curves
over a relevant subinterval of false positive fractions are described in Pepe (2003, page 110) [18]
and are probably more appropriate for comparing screening markers [13].
As mentioned earlier in the discussion about evaluating covariate effects on binary markers,
regression techniques are appropriate when Z is multidimensional or continuous. The same is
true for continuous markers but now regression models for ROC curves must be employed. Some
regression modeling methods for ROC curves have been described. A variety of illustrations are
provided in Pepe 2003 (Chapter 6)[18]. This is a relatively new area of statistical methodology and
methods are evolving rapidly. We refer to Cai and Pepe (2002) and Dodd and Pepe (2003) [22, 23]
for more recent work.
THE INCREMENTAL VALUE OF A MARKER
Now we consider another way in which covariates are often considered. Suppose that there are
some established markers (or predictors) for the outcome that we denote by X1. In considering a
new candidate marker, X2, we want to assess how much classification is improved by using X2 in
addition to X1 [25]. Alternatively, we can ask if there is predictive information in X2 that cannot
be explained by associations with X1. For the purposes of illustration suppose that CA-19-9 is an
established biomarker for pancreatic cancer and we seek to determine the additional contribution of
CA-125 to classification accuracy. Here X1 is CA-19-9 and X2 is CA-125. One common approach
is to treat X1 and X2 as covariates in a logistic regression model.
logitP (D = 1|X1, X2) = α+ β1X1 + β2X2 (1)
and interpret exp(β2) as the odds ratio for the strength of association between X2 and the outcome,
D, after “accounting for” the associations with X1. We do not dispute this. However, as mentioned
earlier, a measure of association is not a characterization of the accuracy of prediction. Using the
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data displayed in Figure 4 we estimate exp(β2) = 2.54 (p = 0.002), a statistically significant
association between CA-125 and pancreatic cancer after controlling for CA-19-9.
In Figure 7 we show the ROC curves for classifying subjects as having pancreatic cancer or not
using CA-19-9 alone and using the combination of CA-19-9 and CA-125 predictors. Assuming that
equation (1) fits the data reasonably well, it is known that the linear combination β1X1 + β2X2 is
the best combination of the markers for discriminating cases from controls [24]. We see that CA-125
adds little to the capacity of CA-19-9 to discriminate between pancreatic cancer cases and controls.
For example, if we are content to accept a 5 percent false positive fraction, we can detect 68 percent
of cases using CA-19-9 alone and 71 percent, using the combination. The tangible benefit of adding
the new marker CA-125 to the existing CA19-9 marker appears to be minimal for the purposes of
classification. That is, the independent contribution of CA-125 to classification is negligible. This
is despite the fact that it has a strong association with disease status that is independent of its
association with CA-19-9.
In our experience this is a rather common phenomenon, that a marker displaying an inde-
pendent association considered strong by traditional epidemiologic standards, does not contribute
meaningfully to improved classification. Another illustration is provided in Kattan (2003)[25]. This
is quite consistent with the observations made earlier in Section 2. Extremely strong associations are
required for meaningful classification accuracy. Again the important message is that the statistical
evaluation of markers for classification should use techniques that directly address classification
accuracy (e.g., ROC curves), rather than traditional logistic regression techniques for assessing
associations.
DISCUSSION
The work in this paper was stimulated by the observation that many studies of predictive/diagnostic
markers continue to use statistical methods based on the odds ratio or relative risk. This is despite
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the fact that such methods are not suited to the task of evaluating classification accuracy. Others
have mentioned that the odds ratio does not quantify the classification accuracy of a marker in-
cluding Kattan (2003), Boyko and Alderman (1990), Emir et al. (2000), and Baker et al. (2002)
[25, 26, 27, 28]. We have presented more detailed discussion, demonstrating the pitfalls of using
the odds ratio for evaluating markers, for evaluating covariate effects on marker performance and
for evaluating the incremental value of a marker over existing predictors. In addition, we have
suggested more appropriate techniques that can be used to address these questions statistically.
References to the literature hopefully will facilitate more widespread adoption of proper methods
in practice.
Although the odds ratio does not characterize a marker’s accuracy for classifying individuals, its
relationship to the relative risk has long made it valuable for characterizing population variations in
risk. A binary marker with relative risk = 3, say, can be used to identify a population with the risk
factor that has 3 times the risk as does the population without the risk factor. This may be used
for targeting prevention or screening strategies. Moreover, clinical trials can often be conducted
more efficiently in such populations. However, as we have noted, such a marker will be a very
inaccurate tool for classifying or predicting risk in individual subjects. Markers that are proposed
for classifying or predicting risk in individual subjects must be held to a much higher standard
than merely being associated with outcome. Their sensitivities and specificities must be shown to
be adequate through appropriate statistical evaluations.
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Table 1: Odds ratios for each quartile relative to the first quartile corresponding to the pairs of
continuous marker distributions shown in Figure 2. Quartiles are based on the marker distributions
in controls. Also shown are the odds ratios per 1 unit increase in X that are displayed in Figure 2.
Quartile
OR per unit of X 1 2 3 4
1.5 reference 1.2 1.4 1.7
2 reference 1.4 1.7 2.4
3 reference 1.6 2.3 4.1
9 reference 2.6 5.2 17.4
16 reference 3.2 7.9 38.7
25 reference 3.8 10.8 73.7
17
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Table 2: Data showing that a covariate (Z) can affect the performance of X as a marker but is
not necessarily an effect modifier in the usual sense of having odds ratios that vary with Z. For
illustration we show 10,000 subjects with Z = 0 and 10,000 with Z = 1. The common odds ratio
is (47×97)/9=506.6 when Z = 0 and Z = 1.
Covariate
Z = 0
Marker D = 0 D = 1
X = 0 846 3
X = 1 54 97
(FPF, TPF) 0.06 0.97
Z = 1
D = 0 D = 1
873 6
27 94
0.03 0.94
18
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Figure Legends
FIGURE 1. The correspondence between the (TPF, FPF) true and false positive fractions, of a bi-
nary marker and the odds ratio, OR. Values of (TPF, FPF) that yield the same OR are connected.
FIGURE 2. Probability distributions of a marker, X , in cases (solid curve) and controls (dashed curve)
that are consistent with the logistic model logitP (D = 1|X) = α+ βX . We assume that X has mean
0 and standard deviation 12 in controls so that a unit increase represents the difference between the 84
th
versus 16th percentiles of X in controls. The marker is normally distributed with the same variance in
cases. The odds ratio per unit increase in X is shown.
FIGURE 3. True versus false positive fractions associated with thresholding the continuous marker
with the criteria X > c for the 6 scenarios shown in Figure 2. Each curve corresponds to one scenario.
Points on the curve correspond to different choices of threshold c  (−∞,∞). Solid circles represent
points associated with using each quartile as the threshold criterion.
FIGURE 4. Frequency distributions of two markers for pancreatic cancer. Source Wieand et al. (1989).
FIGURE 5. ROC curves for the markers shown in Figure 4.
FIGURE 6. Total PSA for 71 prostate cancer cases and 70 age matched controls in the Beta-Carotene
and Retin-A (CARET) study. ROC curves for subjects < 65 years and ≥ 65 years are shown.
FIGURE 7. ROC curves for CA-19-9 and its combination score with CA-125. The combination score is
19
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β1X1 + β2X2 = 1.03log(CA-19-9)+ 0.93log(CA-125).
20
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